ClinConnect ClinConnect Logo
Search / Trial NCT06686888

The Impact of Short-Chain Fatty Acids on Gut Hormone Release After Delivery in the Small and Large Intestine of Healthy Volunteers

Launched by KU LEUVEN · Nov 12, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring how short-chain fatty acids (SCFAs), which are natural substances found in certain foods, affect the release of hormones in the gut that help control feelings of hunger and fullness. The study involves healthy volunteers who will take SCFA capsules either in their small intestine or their colon to see if the location where these acids are delivered makes a difference in hormone release. Participants will have their blood tested at different times after taking the capsules to measure the effects.

To be eligible for this study, participants should be healthy adults aged 18 to 50 with a normal body weight. They should not have any chronic digestive issues or have recently undergone surgeries (except for appendectomy). Additionally, those who are pregnant, breastfeeding, or planning to become pregnant during the study cannot participate. If you join the study, you'll be helping researchers understand how SCFAs influence gut hormone release, which could have important implications for managing appetite and metabolism in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • male and female
  • healthy
  • normal BMI (18.5-25 kg/m\^2)
  • age within 18-50 years
  • Exclusion Criteria:
  • Chronic gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, chronic constipation (less than 3 stools a week) and chronic frequent diarrhoea (more than 3 stools a day)
  • Previous abdominal surgery, except from appendectomy
  • Being on a weight loss, gluten-free, lactose-free, or vegan diet
  • The donation of blood during the last 3 months or suffering from low blood haemoglobin levels
  • The use of antibiotics or other medication that affects the gastrointestinal tract 3 months preceding the study and/or during the study
  • The use of prebiotics or probiotics 2 weeks preceding the study and/or during the study
  • Pregnancy, lactation or wish to become pregnant during the study period
  • Previous or current substance/alcohol dependence or abuse (\> 2 units per day/14 units per week)

About Ku Leuven

KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.

Locations

Leuven, , Belgium

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported